Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity

Synapse

Volumn 63, Issue 2, 2009, Pages 147-151

  Volz, Trent J ^a   Farnsworth, Sarah J ^a   Rowley, Shane D ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Ageing; Efflux; Vesicle

Indexed keywords

DOPAMINE TRANSPORTER; METHAMPHETAMINE; MONOAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; IMMUNOREACTIVITY; MEMBRANE VESICLE; METHODOLOGY; NEUROTOXICITY; NONHUMAN; OSMOSIS; PARKINSON DISEASE; PERINATAL PERIOD; POTENTIOMETRY; PRIORITY JOURNAL; RAT; RAT STRAIN; SUBSTANCE ABUSE; SYNAPTOSOME; TECHNIQUE; TRANSPORT VESICLE; UPREGULATION; WESTERN BLOTTING;

AGE FACTORS; ANIMALS; BLOTTING, WESTERN; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; METHAMPHETAMINE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 59949096554     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20580     Document Type: Article

References (29)

1. Brown JM, Yamamoto BK. 2003. Effects of amphetamines on mitochondrial function: Role of free radicals and oxidative stress. Pharmacol Ther 99:45-53.
2. Collins SL, Wade D, Ledon J, Izenwasser S. 2004. Neurochemical alterations produced by daily nicotine exposure in periadolescent vs. adult male rats. Eur J Pharmacol 502:75-85.
3. Cubells JF, Rayport S, Rajendran G, Sulzer D. 1994. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14:2260-2271.
4. Earles C, Wayment H, Green M, Schenk JO. 1998. Resolution of biogenic amine transporter kinetics by rotating disk electrode voltammetry: Methodology and mechanistic interpretations. Methods Enzymol 296:660-675.
5. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. 2007. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698.
6. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. 1999. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19:2424-2431.
7. Gordon I, Weizman R, Rosenne E, Rehavi M. 1995. Developmental and age-related alterations in rat brain presynaptic dopaminergic mechanisms. Brain Res Dev Brain Res 85:225-228.
8. Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, Kish SJ. 2003. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 87:574-585.
9. Hotchkiss AJ, Morgan ME, Gibb JW. 1979. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci 25:1373-1378.
10. Jenner P. 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13:24-34.
11. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. 2007a. Monitoring the future national survey results on drug use, 1975-2006, Vol. I: Secondary school students (NIH Publication No. 076205). Bethesda, MD: National Institute on Drug Abuse.
12. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. 2007b. Monitoring the future national survey results on drug use, 1975-2006, Vol. II: College students and adults ages 19-45 (NIH Publication No. 07-6206). Bethesda, MD: National Institute on Drug Abuse.
13. Kokoshka JM, Fleckenstein AE, Wilkins DG, Hanson GR. 2000. Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J Neurochem 75:2095-2102.
14. McElvain JS, Schenk JO. 1992. Blockade of dopamine autoreceptors by haloperidol and the apparent dynamics of potassium-stimulated endogenous release of dopamine from and reuptake into striatal suspensions in the rat. Neuropharmacology 31:649-659.
15. Moll GH, Mehnert C, Wicker M, Bock N, Rothenberger A, Ruther E, Huether G. 2000. Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res Dev Brain Res 119:251-257.
16. Ojeda SR, Andrews WW, Advis JP, White SS. 1980. Recent advances in the endocrinology of puberty. Endocr Rev 1:228-257.
17. Patel AP, Cerruti C, Vaughan RA, Kuhar MJ. 1994. Developmentally regulated glycosylation of dopamine transporter. Brain Res Dev Brain Res 83:53-58.
18. Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. 2002. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 449:71-74.
19. Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. 2003. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther 304:1181-1187.
20. Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE. 2005. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity. J Pharmacol Exp Ther 314:1087-1092.
21. Volz TJ, Schenk JO. 2004. L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. Synapse 54:173-182.
22. Volz TJ, Kim M, Schenk JO. 2004. Covalent and noncovalent chemical modifications of arginine residues decrease dopamine transporter activity. Synapse 52:272-282.
23. Volz TJ, Hanson GR, Fleckenstein AE. 2006a. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function. Synapse 60:474-477.
24. Volz TJ, Hanson GR, Fleckenstein AE. 2006b. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. J Neurosci Methods 155:109-115.
25. Volz TJ, Farnsworth SJ, King JL, Riddle EL, Hanson GR, Fleckenstein AE. 2007a. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane- associated vesicles. J Pharmacol Exp Ther 323:738-745.
26. Volz TJ, Hanson GR, Fleckenstein AE. 2007b. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem 101:883-888.
27. Vorhees CV, Reed TM, Morford LL, Fukumura M, Wood SL, Brown CA, Skelton MR, McCrea AE, Rock SL, Williams MT. 2005. Periadolescent rats (P41-50) exhibit increased susceptibility to D-methamphetamine-induced long-term spatial and sequential learning deficits compared to juvenile (P21-30 or P31-40) or adult rats (P51-60). Neurotoxicol Teratol 27:117-134.
28. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. 1980. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151-160.
29. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med 2:699-703.